嗜酸性粒细胞性心肌炎:系统综述
该系统综述纳入239篇文章(含8项观察性研究和274例病例),总结嗜酸性粒细胞性心肌炎(EM)的诊断与治疗现状。心内膜心肌活检(EMB)仍是主要诊断手段(82.4%),17.6%基于临床推理和心脏磁共振(CMR)诊断;糖皮质激素为主要治疗但剂量方案不一,最佳剂量尚无共识。
要点
- EMB是EM诊断的主要手段,指南高度推荐但临床可能未常规使用。
- CMR或有助于合适临床场景下的筛查,CMR诊断者诊断时风险特征更优。
- 糖皮质激素为EM主要治疗,但最佳剂量和方案尚无共识。
核心结论
- EMB仍是EM诊断的主要手段,CMR可能有助于合适临床场景下的筛查。
- 糖皮质激素为EM主要治疗,但最佳剂量方案尚无共识,需大型临床试验进一步探索CMR诊断价值和激素方案。
研究设计与样本
- 遵循PRISMA声明的系统综述,检索MEDLINE和EMBASE从建库至2022年9月10日的同行评议文章。
- 共纳入239篇文章,包括8项观察性研究和274例病例;患者中位年龄45岁。
主要发现
- 初始表现非特异,包括呼吸困难(50.0%)和胸痛(39.4%)。
- 病因多样,最常见为特发性(28.8%)和嗜酸性肉芽肿性多血管炎(19.3%),其他包括药物诱导(13.1%)和高嗜酸性粒细胞综合征(12.8%)。
- 82.4%通过EMB诊断EM,17.6%基于临床推理和CMR诊断。
- CMR诊断的患者诊断时风险特征更好,尤其左心室射血分数更高且更少需要正性肌力或机械循环支持。
关键数值与推荐
- EMB诊断比例82.4%,临床推理联合CMR诊断比例17.6%。
- 初始表现中呼吸困难占50.0%,胸痛占39.4%。
- 病因中特发性占28.8%,嗜酸性肉芽肿性多血管炎占19.3%,药物诱导占13.1%,高嗜酸性粒细胞综合征占12.8%。
临床怎么用
- 临床怀疑EM时应优先考虑EMB以明确诊断。
- 在合适临床场景下可考虑CMR用于筛查,但需进一步研究确认其诊断价值。
- 糖皮质激素为初始治疗选择,但需注意剂量和方案存在差异且无共识。
局限性
- 纳入研究以病例报告和观察性研究为主,可能存在发表偏倚和选择偏倚。
- 糖皮质激素剂量和方案异质性大,无法汇总最佳治疗策略。
- CMR诊断价值需大型临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In clinical practice, patients with eosinophilic myocarditis (EM) may forgo the gold standard diagnostic procedure, endomyocardial biopsy (EMB), although it is highly recommended in guidelines. This systematic review aims to summarise current approaches in diagnosing and treating EM with a particular emphasis on the utilisation and value of alternative diagnostic methods. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, we searched MEDLINE and EMBASE for all peer-reviewed articles using the keywords "eosinophilic myocarditis" from their inception to 10 September 2022. RESULTS: We included 239 articles, including 8 observational studies and 274 cases, in this review. The median patient age was 45 years. Initial presentations were non-specific, including dyspnoea (50.0%) and chest pain (39.4%). The aetiologies of EM were variable with the most common being idiopathic (28.8%) and eosinophilic granulomatosis polyangiitis (19.3%); others included drug-induced (13.1%) and hypereosinophilic syndrome (12.8%). 82.4% received an EM diagnosis by EMB while 17.6% were diagnosed based on clinical reasoning and cardiac MRI (CMR). CMR-diagnosed patients exhibited a better risk profile at diagnosis, particularly higher left ventricular ejection fraction and less need for inotropic or mechanical circulatory supports. Glucocorticoids were the primary treatment with variability in dosages and regimens. CONCLUSION: EMB is the mainstay for diagnostic testing for EM. CMR is potentially helpful for screening in appropriate clinical scenarios. Regarding treatment, there is no consensus regarding the optimal dosage of corticosteroids. Large clinical trials are warranted to further explore the utility of CMR in the diagnosis of EM and steroid regimen in treating EM.
引用
- Techasatian W, Gozun M, Vo K, et al. Eosinophilic myocarditis: systematic review. Heart. 2024. PMID: 37963727. doi:10.1136/heartjnl-2023-323225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。